COR Stock Analysis — Cencora
Sector: Healthcare Distribution
AI Verdict
Cencora is cheap for the growth you're getting, but the moat depends on maintaining its distribution relationships and the huge jump in earnings actually showing up.
Competitive Moat
Cencora operates as a pharmaceutical distributor, leveraging scale and logistics expertise to secure exclusive supply agreements with drug manufacturers and pharmacies. Its defensibility comes from entrenched relationships and regulatory complexity that make switching costly for customers.
Summary
Cencora is on watch due to a forecasted 148.9% jump in earnings next year, driving a sharp drop in its P/E ratio.
Where It Stands
Cencora trades at 16.0x next year's earnings, well below the healthcare sector median of 22x, with analysts forecasting 148.9% EPS growth and a trailing PEG of just 0.27.
Key Metrics
- Trailing P/E: 39.9x
- Forward P/E: 16.0x
- PEG Ratio: 0.27
- Earnings Growth: +1.5%
- Revenue Growth: +0.1%
- Market Cap: $13.9B
- Dividend Yield: 0.01%
- 52-Week High: $377.54
- 52-Week Low: $244.82
Analyst Consensus
15 Buy · 5 Hold · 0 Sell (20 analysts)
Bull Case
With forward EPS growth of 148.9% and a forward P/E of 16.0x, you're paying a low price for explosive earnings acceleration.
Bear Case
If the forward P/E reverts to the sector median of 22x without the expected growth materializing, the stock could see a sharp correction from its current 39.9x trailing P/E level.
Catalyst to Watch
Watch for quarterly earnings reports to confirm whether the massive EPS growth materializes as forecasted.